Nasdaq - QCOR

Healthcare Biotechnology Market Cap - 3.3 Billion Aggressive Growth Stock Anaheim, California 557 Employees

What Does This Company Do? Questcor Pharmaceuticals Inc is a biopharmaceutical company, that provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications.◦ Acthar Gel- treatment of acute exacerbations of

multiple sclerosis ◦ Acthar - $621 Million in sales – approved for 19

conditions◦ Acthar Phase II trials- Treatment for ALS – FDA

request for orphan designation

Roche Holding Novo Nordisk Gilead Science Inc. Lundbeck Novartis Sanofi

SSG Front Front 4A 4A 4B(a) 4B(a) 4A1 4B(a) 4B1 5C U/D

InvestorFutureSales

Growth

FutureEPS

Growth

5-YearHigh P/E

EstHighEPS

5-YearLow P/E

Est.LowEPS

FutureHighPrice

FutureLow Price

Est.LowPrice

TotalReturn

(%)

Upside/Downsid

e

1 15 15.2 22.2 $6.36 7.5 $3.70 $141.20 $27.80 $29.60 21.3% 3.4

2 20 20 20 $9.22 7.0 $3.70 $184.40 $25.90 $25.90 26.2% 3.8

3 18 18 19 $7.17 9.0 $3.14 $136.20 $28.20 $28.20 19.7% 2.8

4 16 16 20 $6.58 7.0 $3.70 $131.60 $25.90 $25.90 18.4% 2.3

5 20 20 22.2 $7.80 7.5 $3.70 $130.00 $27.80 $29.60 18.1% 2.5

6 18.3 20 19 $7.80 7.5 $3.70 $148.20 $27.80 $26.60 21.3% 2.9

7 18 18 20 $7.17 6.9 $3.70 $143.40 $25.50 $21.60 19.6% 2.2

AVERAGE 17.9 18.2 20.3 $7.44 7.49 $3.62 $145.00 $26.99 $26.77 20.7% 2.8MAXIMUM 20 20 22.2 $9.22 9.0 $3.70 $184.40 $28.20 $29.60 26% 3.8

MINIMUM 15 15.2 19 $6.36 6.9 $3.14 $130.00 $25.50 $21.60 18% 2.2

QCOR - Questcor Pharm.

Low debt (10% of Cap’l) Relatively Low PE (16) and pays dividend

(1.70%) (raising quarterly dividend by 20%) VL projects 11% - 22% return Has expanding use of Acthar with great success Mid Cap Named Forbes Best Small Public Company (5yr

est. sales – 51%, est. growth 41%) MS rated 5.0 – Buy Yahoo 1.5 – Buy Motley Fool Quote “Simply put, Questcor looks

very cheap”

Tremendous Growth – 52 weeks - $19.90 – $74.76

Business appears to be focused on the development of one major drug

Club portfolio contains 3 biotech stocks(?) Zacks - 3 VL “some reimbursement concerns”

“long term investors should consider these shares”

Buy